ATE72241T1 - 2-amino-4-morpholino-6-propyl-1,3,5-triazine. - Google Patents

2-amino-4-morpholino-6-propyl-1,3,5-triazine.

Info

Publication number: ATE72241T1
Authority: AT; Austria
Prior art keywords: alkyl; morpholino; propyl; amino; alkyleneimino
Prior art date: 1988-08-16

Application number

AT89870120T

Other languages

English (en)

Inventor

Eric Cossement

Jean Gobert

Roland Boydens

Jacques Mathieu

Original Assignee

Ucb Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-08-16

Filing date

1989-07-28

Publication date

1992-02-15

1989-07-28 Application filed by Ucb Sa filed Critical Ucb Sa

1992-02-15 Application granted granted Critical

1992-02-15 Publication of ATE72241T1 publication Critical patent/ATE72241T1/de

Links

GOIPIEMTOZZMNH-UHFFFAOYSA-N 4-morpholin-4-yl-6-propyl-1,3,5-triazin-2-amine Chemical compound CCCC1=NC(N)=NC(N2CCOCC2)=N1 GOIPIEMTOZZMNH-UHFFFAOYSA-N 0.000 title abstract 2
125000000217 alkyl group Chemical group 0.000 abstract 5
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 abstract 2
125000003710 aryl alkyl group Chemical group 0.000 abstract 2
125000004432 carbon atom Chemical group C* 0.000 abstract 2
229910052739 hydrogen Inorganic materials 0.000 abstract 2
239000001257 hydrogen Substances 0.000 abstract 2
125000002768 hydroxyalkyl group Chemical group 0.000 abstract 2
208000024827 Alzheimer disease Diseases 0.000 abstract 1
206010012289 Dementia Diseases 0.000 abstract 1
101100295738 Gallus gallus COR3 gene Proteins 0.000 abstract 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
125000004423 acyloxy group Chemical group 0.000 abstract 1
125000005041 acyloxyalkyl group Chemical group 0.000 abstract 1
230000032683 aging Effects 0.000 abstract 1
125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
125000004171 alkoxy aryl group Chemical group 0.000 abstract 1
125000003545 alkoxy group Chemical group 0.000 abstract 1
125000002877 alkyl aryl group Chemical group 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
125000006213 aryl hydroxyalkyl group Chemical group 0.000 abstract 1
125000004104 aryloxy group Chemical group 0.000 abstract 1
230000003542 behavioural effect Effects 0.000 abstract 1
230000001149 cognitive effect Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 1
125000004663 dialkyl amino group Chemical group 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
125000003106 haloaryl group Chemical group 0.000 abstract 1
150000002431 hydrogen Chemical group 0.000 abstract 1
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
125000005350 hydroxycycloalkyl group Chemical group 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
208000011580 syndromic disease Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
- C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/08—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Ophthalmology & Optometry (AREA)
Neurosurgery (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Cosmetics (AREA)

AT89870120T 1988-08-16 1989-07-28 2-amino-4-morpholino-6-propyl-1,3,5-triazine. ATE72241T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB888819493A GB8819493D0 (en)	1988-08-16	1988-08-16	2-amino-4-morpholino-6-propyl-1 3 5-triazines
EP89870120A EP0356413B1 (de)	1988-08-16	1989-07-28	2-Amino-4-morpholino-6-propyl-1,3,5-triazine

Publications (1)

Publication Number	Publication Date
ATE72241T1 true ATE72241T1 (de)	1992-02-15

Family

ID=10642235

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT89870120T ATE72241T1 (de)	1988-08-16	1989-07-28	2-amino-4-morpholino-6-propyl-1,3,5-triazine.

Country Status (28)

Country	Link
US (1)	US4956367A (de)
EP (1)	EP0356413B1 (de)
JP (1)	JPH02108675A (de)
KR (1)	KR0136108B1 (de)
AT (1)	ATE72241T1 (de)
AU (1)	AU614247B2 (de)
CA (1)	CA1317944C (de)
CY (1)	CY1709A (de)
DE (1)	DE68900794D1 (de)
DK (1)	DK171698B1 (de)
ES (1)	ES2038849T3 (de)
FI (1)	FI102065B1 (de)
GB (1)	GB8819493D0 (de)
GR (1)	GR3004267T3 (de)
HK (1)	HK95693A (de)
HU (1)	HUT58087A (de)
IE (1)	IE61205B1 (de)
IL (1)	IL91243A (de)
LT (1)	LT3601B (de)
MY (1)	MY105008A (de)
NO (1)	NO179206C (de)
NZ (1)	NZ230290A (de)
PL (2)	PL161591B1 (de)
PT (1)	PT91438B (de)
RU (3)	RU1806142C (de)
SG (1)	SG27893G (de)
UA (1)	UA11064A (de)
ZA (1)	ZA896222B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9024617D0 (en) *	1989-12-05	1991-01-02	Ici Plc	Heterocyclic compounds
GB9008818D0 (en) *	1990-04-19	1990-06-13	Ici Plc	Amine derivatives
IT1240690B (it) *	1990-04-30	1993-12-17	Ciba Geigy Ag	Composti piperdin-triazinici atti all'impiego come stabilizzanti per materiali organici
GB9116039D0 (en) *	1991-07-25	1991-09-11	Ucb Sa	Substituted cyclopropylamino-1,3,5-triazines

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3549755A (en) *	1968-03-27	1970-12-22	Shell Oil Co	Use of 2-trichloromethyl-4-morpholinoor piperazino-6-substituted-s-triazines for inducing depressant effects in animals
JPS4969688A (de) *	1972-11-02	1974-07-05
FR2262512A1 (en) *	1974-03-01	1975-09-26	Synthelabo	2,4,6-Tri-substd. -1,3,5-triazines - with analgesic and psychotropic activity

1988
- 1988-08-16 GB GB888819493A patent/GB8819493D0/en active Pending
1989
- 1989-07-28 EP EP89870120A patent/EP0356413B1/de not_active Expired - Lifetime
- 1989-07-28 AT AT89870120T patent/ATE72241T1/de not_active IP Right Cessation
- 1989-07-28 DE DE8989870120T patent/DE68900794D1/de not_active Expired - Lifetime
- 1989-07-28 ES ES198989870120T patent/ES2038849T3/es not_active Expired - Lifetime
- 1989-08-07 FI FI893714A patent/FI102065B1/fi not_active IP Right Cessation
- 1989-08-08 US US07/390,878 patent/US4956367A/en not_active Expired - Fee Related
- 1989-08-08 IL IL9124389A patent/IL91243A/en not_active IP Right Cessation
- 1989-08-09 MY MYPI89001088A patent/MY105008A/en unknown
- 1989-08-09 CA CA000607834A patent/CA1317944C/en not_active Expired - Fee Related
- 1989-08-11 PT PT91438A patent/PT91438B/pt not_active IP Right Cessation
- 1989-08-11 PL PL89283603A patent/PL161591B1/pl unknown
- 1989-08-11 PL PL1989281021A patent/PL161161B1/pl unknown
- 1989-08-14 DK DK398189A patent/DK171698B1/da active
- 1989-08-14 NZ NZ230290A patent/NZ230290A/xx unknown
- 1989-08-15 JP JP1210547A patent/JPH02108675A/ja active Pending
- 1989-08-15 RU SU894614758A patent/RU1806142C/ru active
- 1989-08-15 NO NO893279A patent/NO179206C/no unknown
- 1989-08-15 IE IE261989A patent/IE61205B1/en not_active IP Right Cessation
- 1989-08-15 AU AU39917/89A patent/AU614247B2/en not_active Ceased
- 1989-08-15 ZA ZA896222A patent/ZA896222B/xx unknown
- 1989-08-15 HU HU894192A patent/HUT58087A/hu unknown
- 1989-08-16 KR KR1019890011696A patent/KR0136108B1/ko not_active Expired - Fee Related
- 1989-12-21 UA UA4742645A patent/UA11064A/uk unknown
- 1989-12-21 RU SU894742645A patent/RU1822403C/ru active
1990
- 1990-08-20 RU SU904830673A patent/RU1838312C/ru active
1992
- 1992-04-02 GR GR920400622T patent/GR3004267T3/el unknown
1993
- 1993-03-16 SG SG278/93A patent/SG27893G/en unknown
- 1993-08-03 LT LTIP829A patent/LT3601B/lt not_active IP Right Cessation
- 1993-09-16 HK HK956/93A patent/HK95693A/xx not_active IP Right Cessation
1994
- 1994-01-14 CY CY170994A patent/CY1709A/xx unknown

Also Published As

Publication number	Publication date
IE61205B1 (en)	1994-10-19
NO893279L (no)	1990-02-19
LT3601B (en)	1995-12-27
IL91243A (en)	1995-05-26
HUT58087A (en)	1992-01-28
JPH02108675A (ja)	1990-04-20
GR3004267T3 (de)	1993-03-31
MY105008A (en)	1994-07-30
CY1709A (en)	1994-01-14
GB8819493D0 (en)	1988-09-21
NO179206C (no)	1996-08-28
US4956367A (en)	1990-09-11
CA1317944C (en)	1993-05-18
RU1806142C (ru)	1993-03-30
FI893714A7 (fi)	1990-02-17
EP0356413A1 (de)	1990-02-28
UA11064A (uk)	1996-12-25
AU3991789A (en)	1990-04-05
ES2038849T3 (es)	1993-08-01
DE68900794D1 (en)	1992-03-12
KR0136108B1 (ko)	1998-04-25
AU614247B2 (en)	1991-08-22
NZ230290A (en)	1991-10-25
SG27893G (en)	1993-06-25
PL161161B1 (pl)	1993-05-31
FI102065B (fi)	1998-10-15
NO179206B (no)	1996-05-20
ZA896222B (en)	1990-05-30
IL91243A0 (en)	1990-03-19
DK398189D0 (da)	1989-08-14
RU1822403C (ru)	1993-06-15
FI102065B1 (fi)	1998-10-15
LTIP829A (en)	1995-02-27
PT91438B (pt)	1995-05-04
HK95693A (en)	1993-09-24
DK398189A (da)	1990-02-17
EP0356413B1 (de)	1992-01-29
FI893714A0 (fi)	1989-08-07
KR900003165A (ko)	1990-03-23
PL161591B1 (pl)	1993-07-30
IE892619L (en)	1990-02-16
NO893279D0 (no)	1989-08-15
DK171698B1 (da)	1997-03-24
RU1838312C (ru)	1993-08-30
PT91438A (pt)	1990-03-08

Legal Events

Date	Code	Title	Description
1992-11-15	UEP	Publication of translation of european patent specification
2000-04-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE59003587D1 (de)	1994-01-05	Diarylacetylene, ihre Herstellung und Verwendung.
ATE75942T1 (de)	1992-05-15	Verwendung von 2-amino-4-morpholino-6-propyl1,3,5-triazin zur herstellung eines medikaments zur behandlung kognitiver und mentaler erkrankungen.
GR3002051T3 (en)	1992-12-30	3-oxadiazolyl and 3-carboxylic-acid beta-carboline derivatives, their preparation and their use as medicaments
DE59006868D1 (de)	1994-09-29	2-Alkyl-4-arylmethylaminochinoline, ihre Verwendung und daraus hergestellte Arzneimittel.
ATE72241T1 (de)	1992-02-15	2-amino-4-morpholino-6-propyl-1,3,5-triazine.
BR9916046A (pt)	2001-10-02	Composto, composição farmacêutica, e, processos para inibir a replicação de um vìrus herpes e para tratamento de um paciente que sofra de uma infecção do vìrus herpes
DE3876536D1 (de)	1993-01-21	Oxadiazol-pyrimidinone, ihre herstellung und ihre kosmetische und dermopharmazeutische verwendung.
IL92280A0 (en)	1990-07-26	Oxime ether derivatives,their preparation and fungicidal compositions containing them
IL90043A0 (en)	1989-12-15	Sulfonanilides,their preparation and pharmaceutical compositions containing them
ATE97130T1 (de)	1993-11-15	13-brom und 13, 14-dibrom-ergoline, ihre herstellung und verwendung in arzneimitteln.